The Drug-Specific Propensity Regarding the Acquisition of Fluoroquinolone Resistance in Escherichia coli: An in vitro Challenge and DNA Mutation Analysis
Takumi Sato,Ryota Ito,Masato Kawamura,Shigeru Fujimura
DOI: https://doi.org/10.2147/idr.s428383
2023-09-26
Infection and Drug Resistance
Abstract:Takumi Sato, 1 Ryota Ito, 1, 2 Masato Kawamura, 1 Shigeru Fujimura 1 1 Division of Clinical Infectious Diseases & Chemotherapy, Tohoku Medical and Pharmaceutical University, Sendai, Japan; 2 Department of Pharmacy, Japan Labor Health and Welfare Organization Tohoku Rosai Hospital, Sendai, Japan Correspondence: Takumi Sato, Division of Clinical Infectious Diseases & Chemotherapy, Tohoku Medical and Pharmaceutical University, 4-4-1, Komatsushima, Aoba-ku, Sendai, 981-8558, Japan, Tel +81227270176, Fax +81227270177, Email Objective: Many fluoroquinolones, such as ciprofloxacin, are used clinically. We investigated the relationship between resistance acquisition and exposure duration in each drug through the exposure of fluoroquinolone to Escherichia coli clinical isolates in vitro. Methods: Eleven E. coli clinical isolates were exposed to each fluoroquinolone, ie, ciprofloxacin, levofloxacin, sitafloxacin, garenoxacin, and lascufloxacin, with the concentration of the mutant selection window for 5 days; these procedures were repeated 5-times. In addition, the DNA sequence in the quinolone-resistance determining region (QRDR) and the expression level in the drug efflux pump acrA were analyzed to determine the resistance mechanism. Results: Although resistant strains were not detected after 5 to 10 days of exposure to fluoroquinolone, after 25 days of exposure to ciprofloxacin and levofloxacin, 100% and 45% of isolates acquired resistance, respectively. Due to 25 days of exposure to sitafloxacin, garenoxacin, and lascufloxacin, MIC measurement was elevated 2- to 4096-fold for those of the parental strain, and the cross-resistance rate to levofloxacin was 72%, 54%, and 27%, respectively. In strains with high fluoroquinolone resistance, acrA overexpression was observed in addition to QRDR mutation. Conclusion: In our findings, fluoroquinolone resistance was not observed in the E. coli strain after 5- to 10-days of exposure. However, resistance acquisition was detected frequently after 15- to 25-days of exposure. Among fluoroquinolones, lascufloxacn had the least impact on the resistance acquisition in E. coli . Plain Language Summary: The need to combat quinolone-resistant E. coli is urgent. The resistance acquisition tendency of E. coli varies according to the drug used. After 25 days of exposure, 45% of E. coli showed levofloxacin resistance. Lascufloxacin may have the lowest influence on resistance acquisition to regular E. coli . Keywords: Escherichia coli , respiratory quinolone, mutant selection window, quinolone-resistance determining region, efflux pump The recent increase in fluoroquinolone resistance in Escherichia coli is one of the most severe threats to public health. 1 In the least surveillance, the frequency of fluoroquinolone-resistant E. coli has been reported at 22% in Europe, 2 21% in the United States, 3 and 38% in Japan. 4 The increase of such quinolone-resistant E. coli has been attributed to the use of fluoroquinolones. Subsequently, the guidelines of the Infectious Diseases Society of America and European Society of Clinical Microbiology and Infectious Diseases were reviewed, 5 and a policy to refrain from quinolone consumption was implemented. However, the epidemic of fluoroquinolone-resistance E. coli continues to increase. There are two main reasons for the expansion of drug-resistant E. coli . The first is the expansion of mobile genetic elements across bacterial species, mediated by a plasmid including an extended spectrum of beta-lactamase. The second is inappropriate use of antibacterial agents. Generally, a quinolone is selected as treatment for respiratory or urinary tract infections. In addition, the on-period for respiratory infection is longer than that of urinary tract infection. 6 Respiratory quinolones such as levofloxacin, sitafloxacin, garenoxacin, and lascufloxacin are sometimes used to manage respiratory infections such as pneumonia or lung abscesses. 7 Thus, respiratory quinolone brands have increased recently. It is known that the fluoroquinolone resistance mechanism is the mutation in the quinolone-resistance determining region (QRDR) of gyrA / parC and the high expression of efflux pumps such as AcrAB. In this study, to elucidate the impact of respiratory quinolone on the development of fluoroquinolone resistance in E. coli , we performed an in vitro challenge against E. coli clinical isolates and analyzed QRDR DNA mutation. A total of 40 E. c -Abstract Truncated-
pharmacology & pharmacy,infectious diseases